-
For Arbutus' Hepatitis B Treatment, 'Liver Safety Risk Overwhelms Promising Efficacy'
Tuesday, December 13, 2016 - 10:03am | 360Arbutus Biopharma Corp (NASDAQ: ABUS) reported additional data from the Phase II trial of ARB-1467, its RNAi drug for the treatment of chronic hepatitis B virus (HBV). Citing safety concerns related to ARB-1467, Chardan Capital Markets’ Madhu Kumar downgraded the rating on the company from...
-
Chardan Upgrades Regeneron; Cites Fovista Failure, Stock's Recent Underperformance
Monday, December 12, 2016 - 9:28am | 335Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has underperformed Amgen, Inc. (NASDAQ: AMGN) as well as the NBI year-to-date in 2016, while a key threat, in the form of Ophthotech Corp (NASDAQ: OPHT)'s Fovista, has been eliminated. Chardan Capital’s Gbola Amusa upgraded the rating on Regeneron...
-
Chardan Downgrades Ophthotech As Fovista Fails Phase III Trials For Wet AMD
Monday, December 12, 2016 - 9:21am | 255On December 12, Ophthotech Corp (NASDAQ: OPHT) announced that its Phase III trials, OPH1002 and OPH1003, revealed negative results in wet age-related macular degeneration (AMD). Chardan Capital’s Gbola Amusa downgraded the rating on the company from Buy to Neutral, while lowering the...
-
4 Possible Catalysts On Eyegate's Horizon
Tuesday, December 6, 2016 - 12:17pm | 366Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) reported additional encouraging results from the Phase 1b/2a clinical study of its lead product, EGP-437, in patients who have undergone cataract surgery. Terming the lead compound as “promising,” Chardan Capital Markets' Keay Nakae...
-
Chardan: Watch Wearable Maker Vuzix Into CES
Monday, December 5, 2016 - 11:17am | 362Vuzix Corporation (NASDAQ: VUZI) has recently raised $14 million in an equity offering. The company is heading into the CES (Consumer Electronics Show) with a robust balance sheet as well as “a broad and expanding product line,” Chardan Capital Markets’ James McIlree said in a...
-
Alnylam Is Now The Leader In The Clinical HBV RNAi Therapy Space
Wednesday, November 30, 2016 - 10:32am | 350Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced the discontinuation of all its clinical RNAi programs, citing safety issues. This development could boost Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)'s market share in both HBV (hepatitis B virus) RNAi and (alpha-1 antitrypsin), Chardan...
-
WageWorks Shares Could Rise 16% Over Next Year
Wednesday, November 30, 2016 - 10:04am | 257Channel checks indicate strong growth for Wageworks Inc (NYSE: WAGE) over the next couple of years from multiple sources, Chardan Capital Markets’ Steven Wardell said in a report. He initiated coverage on the company with a Buy rating and a price target of $86. WageWorks’ growth over...
-
Arrowhead Pharma Downgraded Following EX-1 RNAi Program Discontinuations
Wednesday, November 30, 2016 - 8:28am | 252Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced it was discontinuing all its clinical RNAi programs. All these programs use the dynamic polyconjugate (DPC) platform in the EX-1 delivery vehicle. Chardan Capital’s Madhu Kumar downgraded the rating on the company to Neutral, while...
-
Amicus Therapeutics: Here's The Good News
Tuesday, November 29, 2016 - 2:12pm | 302Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) plunged more than 22 percent on news that the FDA seeks a pivotal "cross-over" study of Galafold (migalastat) in treatment-naive Fabry disease patients with gastrointestinal (GI) symptoms to approve the drug. FDA Requests Additional...
-
Teladoc Shares Could Rise 40% Over The Next Year
Wednesday, November 16, 2016 - 10:08am | 305Recent channel checks indicate robust growth for Teladoc Inc (NYSE: TDOC) over the next couple of years, backed by strong demand for telehealth, Chardan Capital Markets’ Steven Wardel said in a report. He initiated coverage of the company with a Buy rating and a price target of $24....
-
Chardan Recommends Selling Clovis Oncology
Tuesday, October 25, 2016 - 7:47am | 312Clovis Oncology Inc’s (NASDAQ: CLVS) lead asset rucaparib has a poor risk-benefit profile. The candidate’s lack of efficacy over current treatments and safety signals represent “considerable risks” ahead of its PDUFA in February next year, Chardan Capital Markets’...
-
Novartis A Buy At Chardan
Tuesday, September 20, 2016 - 10:15am | 355Chardan Capital’s Gbola Amusa believes Novartis AG (ADR) (NYSE: NVS) has the “potential for excess shareholder returns over the long-term by generating shared value for society through performance on 1) disruptive or sustainable innovation, 2) access to medicines initiatives, and/or 3)...
-
3 Turnaround Stories Getting Love From Sell-Side Analysts
Tuesday, August 9, 2016 - 9:05am | 380Taking a look back at last week's Benzinga Pro headlines, there are several stocks whose turnaround story have been under the watchful eye of sell-side analysts. The Headline: "Chardan Analyst Believe iPass Inc. (NASDAQ: IPAS)' Turnaround Strategy Is Working - also upgraded the...
-
Chardan Analyst Believe iPass' Turnaround Strategy Is Working
Thursday, August 4, 2016 - 9:53am | 281iPass Inc. (NASDAQ: IPAS) reported its 2Q revenue ahead of expectations. Chardan Capital Markets’ James McIlree upgraded the rating on iPass to Buy, with a price target of $2, saying that the company’s turnaround strategy seemed to be working. iPass reported its 2Q revenue at $16.5...
-
Weak Competition, Favorable Regulatory Environment Among Tailwinds For Sunworks
Thursday, August 4, 2016 - 9:04am | 259Sunworks Inc (NASDAQ: SUNW) has attractive growth opportunities in its current markets, while also seeking to expand via acquisition, Chardan Capital Markets’ James McIlree said in a report. He initiated coverage of the company with a Buy rating and a $5 price target. Sunworks caters to...